Oxyrane develops enzyme replacement therapies (ERTs) for the treatment of lysosomal storage diseases (LSDs) - where an inherited, deficient enzyme leads to undesired cellular waste accumulation and disease.
Oxyrane engineers these deficient /absent enzymes to improve their targeting and activity. Our lead product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells.
Oxyrane develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The expression host has been engineered to produce proteins with a specific "targeting" sugar structure required for effective intracellular localisation - mannose 6-phosphate (M6P).
Registered in 2006, Oxyrane is a private, venture-capital funded company with a head office in Manchester, England and research operations in Gent, Belgium.